Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
Luepker
Russell V
RV
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 S Second St, Ste 300, Minneapolis, MN 55454, USA. luepker@epi.umn.edu
D016907:Adverse Drug Reaction Reporting Systems; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004345:Drug Industry; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D056737:Safety-Based Drug Withdrawals; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib